John E. Davis Sells 15,100 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 15,100 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $356,511.00. Following the transaction, the insider now owns 208,778 shares in the company, valued at approximately $4,929,248.58. This represents a 6.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Artivion Stock Up 3.1 %

Shares of NYSE:AORT opened at $24.15 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. Artivion, Inc. has a 52-week low of $19.11 and a 52-week high of $32.33. The firm has a market capitalization of $1.02 billion, a P/E ratio of -1,207.25 and a beta of 1.79. The stock has a 50 day moving average price of $28.66 and a 200-day moving average price of $27.72.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million for the quarter, compared to analysts’ expectations of $100.82 million. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Squarepoint Ops LLC grew its holdings in Artivion by 30.8% in the fourth quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock worth $1,021,000 after purchasing an additional 8,404 shares during the period. Tidal Investments LLC grew its stake in shares of Artivion by 14.5% in the 4th quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock worth $5,141,000 after buying an additional 22,804 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Artivion during the 4th quarter valued at approximately $64,000. Point72 Asset Management L.P. purchased a new position in Artivion during the fourth quarter valued at $5,573,000. Finally, ProShare Advisors LLC boosted its holdings in Artivion by 44.7% in the fourth quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after acquiring an additional 3,683 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

AORT has been the subject of several research analyst reports. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a report on Tuesday, December 10th. Stifel Nicolaus cut their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Finally, Needham & Company LLC reduced their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.